Home › Pain After Surgery › NCT07539623

Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery

Who can join

Ages 18 to 85 · All sexes

Inclusion Criteria:

To be eligible to participate in this study, an individual must meet all of the following criteria:

* Adults 18-85 years old
* Scheduled to undergo cardiac procedures via sternotomy or bariatric surgery (laparoscopic or open)
* All genders

Exclusion Criteria:

Any individual who meets any of the following criteria will be excluded from participation in this study:

* ASA Class V
* Urgent or emergent surgery
* Contraindications to administration of Suzetrigine (e.g. concomitant use of strong CYP3A inhibitors)
* History of substance use disorder or chronic opioid use
* Reoperation
* Patient refusal or inability to consent
* Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and
* Clarithromycin)
* Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin)

About the study

This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-operative opioid consumption and pain scores.

What is being tested

• Suzetrigine (drug)
• Placebo (drug)

Sponsor: Icahn School of Medicine at Mount Sinai · Participants: 235 · Started: May 1, 2026

Contact the study team

• Himani Bhatt, DO · Phone: 212-523-2500
• Michael Lazar, MD · Phone: 212-523-2500

Official record on ClinicalTrials.gov — NCT07539623

Locations in the U.S.

Conditions

• Pain After Surgery

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.